Could Reference Rituximab's New EU Indication Help It Stave Off Biosimilars?
March 20th 2019
By The Center for Biosimilars Staff
ArticleThe European Commission has approved Roche’s innovator rituximab, sold in Europe as MabThera, for the treatment of pemphigus vulgaris (PV), a rare autoimmune disorder. The approval marks the first biologic approval for PV in the European Union, and the first major new therapeutic option in 60 years.